Assessment of Bone Quality in Osteoporosis Treatment with Bone Anabolic Agents: Really Something New?

@article{Ulivieri2018AssessmentOB,
  title={Assessment of Bone Quality in Osteoporosis Treatment with Bone Anabolic Agents: Really Something New?},
  author={Fabio Massimo Ulivieri and Renata Caudarella and Marzia Camisasca and Daniela M Cabrini and Ilaria Merli and Carmelo Messina and Luca Petruccio Piodi},
  journal={Current rheumatology reviews},
  year={2018},
  volume={14 1},
  pages={
          53-61
        }
}
Osteoporosis is a chronic pathologic condition, particularly of the elderly, in which a reduction of bone mineral density (BMD) weakens bone, leading to the so-called fragility fractures, most often of spine and femur. The gold standard exam for the quantitative measurement of BMD is the dual X-ray photon absorptiometry (DXA), a radiological method. However, a relevant number of fragility fractures occurs in the range of normal BMD values, meaning that also qualitative aspects of bone play a… CONTINUE READING